RedHill Biopharma (NASDAQ:RDHL) research coverage began at StockNews.com

StockNews.com has begun coverage of the stock RedHill Biopharma (NASDAQ:RDHL – Get a Free Report) in a report published on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Stock Performance

Shares of NASDAQ:RDHL opened at $9.02 on Friday. RedHill Biopharma has a 52 week low of $6.43 and a 52 week high of $82.00. The company’s fifty day moving average is $225.44 and its 200 day moving average is $278.18.

Institutional investors weigh in on RedHill Biopharma

A hedge fund recently increased its stake in RedHill Biopharma. Gagnon Securities LLC increased its position in RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) by 32.1% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 118,360 shares of the biotechnology company’s stock after acquiring an additional 28,771 shares during the period. Gagnon Securities LLC owned about 0.40% of RedHill Biopharma worth $63,000 as of its most recent SEC filing. Institutional investors own 7.20% of the company’s shares.

About RedHill Biopharma

(Get a free report)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses primarily on gastrointestinal and infectious diseases. The Company develops and markets Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of traveler’s diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development, include opaganib for the treatment of hospitalized patients with severe COVID-19 SARS-CoV-2 pneumonia, unresectable advanced cholangiocarcinoma, prostate cancer and nuclear radiation protection; RHB-107 (upamostat) for the treatment of outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea and antiemetic oncology support; and RHB-204 for pulmonary infections with nontuberculous mycobacteria caused by the mycobacterium avium complex.

Further reading

Get news and reviews for RedHill Biopharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for RedHill Biopharma and related companies with MarketBeat.com’s FREE daily email newsletter.